GlobeNewsWire
14 Jun 2026, 07:15 UTC · 22w ago
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Impact · against what's priced in
Legend Biotech's first clinical proof-of-concept for LB2501 is a material positive catalyst, validating a disruptive 'in vivo' CAR-T approach. The high efficacy (100% ORR at DL2) and absence of severe toxicity (no ICANS or SAEs) significantly derisk the candidate's potential to simplify cell therapy administration.
- LEGN+0.80
No priced-in read yet





